Albuminar Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to long standing clinical use of albumin, effectiveness in shock treatment, growth of trauma care, availability of plasma supplies, hospital reliance on volume expanders.

The growth in the forecast period can be attributed to increasing surgical procedures, growth in ICU admissions, rising burn injury cases, expanding healthcare infrastructure, steady demand in emergency medicine. Major trends in the forecast period include continued use of plasma derived albumin, high demand in emergency care, stable adoption in volume expansion therapy, use in critical and surgical settings, reliance on established clinical protocols.

The increasing incidence of burn injuries is expected to drive the growth of the Albuminar market in the coming years. The rise in burn injuries is attributed to factors such as greater exposure to household hazards, workplace accidents, and fire-related incidents. Environmental factors, including wildfires and industrial accidents, along with expanding urban populations, have further contributed to higher rates of burn injuries. Albuminar (human albumin) is widely used in the treatment of burn patients to restore plasma volume, maintain blood pressure, and prevent shock, particularly during the initial phases of care. For example, in August 2024, according to a report by the American Burn Association, a US-based organization dedicated to burn research, rehabilitation, and prevention, there were 32,540 burn cases reported in 2023, compared with 30,135 cases in 2022, contributing to a total of 156,073 cases over a five-year period. Consequently, the rising incidence of burn injuries is supporting the growth of the Albuminar market.

The growing number of surgical procedures is also expected to propel the growth of the Albuminar market. The increasing prevalence of chronic lifestyle-related diseases has driven advancements in medical technologies, leading to a higher demand for surgical interventions. These innovations have improved the effectiveness and accessibility of surgeries, helping address rising healthcare needs. Albuminar is commonly used during surgical procedures to restore blood volume, maintain circulatory stability, and correct hypoalbuminemia, especially in major trauma cases, cardiac surgeries, liver transplants, and orthopedic operations. For example, in December 2023, according to the UK Health Security Agency, a UK-based government agency, coronary artery bypass graft surgeries increased in 2023, reaching 27,524 procedures compared with previous years. As a result, the rising volume of surgical procedures is contributing to the growth of the Albuminar market.

Companies operating in the Albuminar market are increasingly adopting strategic partnership approaches to improve technology integration and expand their market presence. Strategic partnerships involve collaborative arrangements between organizations that pool resources, expertise, and capabilities to achieve shared objectives. For instance, in April 2023, Kedrion Biopharma Inc., a US-based pharmaceutical manufacturer, introduced a human albumin product into the Chinese market following product approval from China’s National Institutes for Food and Drug Control for Bio Products Laboratory (BPL), a UK-based company. This collaboration strengthens Kedrion’s global position in plasma-derived products, supported by a workforce of over 5,000 employees worldwide and a network of 73 plasma collection centers in the United States and five in the Czech Republic.

Major companies operating in the albuminar market are CSL Behring LLC.

North America was the largest region in the Albuminar market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the albuminar market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the albuminar market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs have affected the albuminar market by increasing costs related to plasma collection, processing equipment, and cold chain logistics. These impacts are most visible in regions dependent on imported plasma derivatives such as Asia Pacific. Hospitals face moderate pricing pressure for albumin infusions. At the same time, tariffs are encouraging regional plasma fractionation and strengthening domestic supply chains.

The albuminar market research report is one of a series of new reports that provides albuminar market statistics, including albuminar industry global market size, regional shares, competitors with a albuminar market share, detailed albuminar market segments, market trends and opportunities, and any further data you may need to thrive in the albuminar industry. This albuminar market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Albuminar is a human albumin solution obtained from plasma and is used to restore blood volume and maintain oncotic pressure in the body. It is commonly prescribed for conditions such as hypovolemia, hypoalbuminemia, and shock. Administered intravenously, it helps stabilize fluid balance in critically ill or injured patients.

The main formulation types of Albuminar include human serum albumin, bovine serum albumin, and recombinant albumin. Human serum albumin (HSA) is the most abundant protein in human blood plasma, produced by the liver, and plays a vital role in maintaining oncotic pressure by keeping fluid within the bloodstream and preventing leakage into surrounding tissues. The indications include shock management, burns, and hypoalbuminemia, and the end users include hospitals and clinics, pharmaceutical and biotechnology companies, and research institutes.

The albuminar market consists of sales of Albuminar 5% and Albuminar 20%. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.